Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in receptor-selective retinoids.

S Nagpal1, R A Chandraratna

  • 1Retinoid Research, Department of Biology and Chemistry, Allergan Inc., Irvine, CA-92713, USA.

Current Pharmaceutical Design
|June 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion.

ESMO open·2026
Same author

Multi-omics analysis identifies potential microbial and metabolite diagnostic biomarkers of bacterial vaginosis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2024
Same author

Anaesthesia for vascular emergencies - a state of the art review.

Anaesthesia·2022
Same author

DSC Perfusion MRI-Derived Fractional Tumor Burden and Relative CBV Differentiate Tumor Progression and Radiation Necrosis in Brain Metastases Treated with Stereotactic Radiosurgery.

AJNR. American journal of neuroradiology·2022
Same author

Rheumatoid arthritis synovial microenvironment induces metabolic and functional adaptations in dendritic cells.

Clinical and experimental immunology·2020
Same author

Perfusion MRI-Based Fractional Tumor Burden Differentiates between Tumor and Treatment Effect in Recurrent Glioblastomas and Informs Clinical Decision-Making.

AJNR. American journal of neuroradiology·2019
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
Same journal

Pharmacological Insights into Medicinal Plants and Phytomolecules for the Management of Alopecia with Mechanistic Perspectives and Therapeutic Potential.

Current pharmaceutical design·2026
Same journal

Addressing Challenges, Regulatory Shifts, and the Need for Cost-Effective Alternatives for Complex Topical Formulations.

Current pharmaceutical design·2026
Same journal

The Mechanism of Huaiqihuang in the Treatment of Nephrotic Syndrome: An Integrated Study Based on Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and Experimental Validation.

Current pharmaceutical design·2026
Same journal

Resveratrol and the NLRP3 Inflammasome: Unlocking the Anti-inflammatory Potential of a Natural Compound.

Current pharmaceutical design·2026
Same journal

The Use of Hemostatic Agents in Traumatic Bleeding: One Size Does Not Fit All.

Current pharmaceutical design·2026
See all related articles

Retinoids, including all trans-retinoic acid (RA), offer therapeutic benefits for skin conditions and cancers. New receptor-selective retinoids show promise for treating diabetes and other diseases.

Area of Science:

  • Dermatology
  • Oncology
  • Endocrinology

Background:

  • Natural and synthetic retinoids possess anti-proliferative, differentiation-normalizing, and anti-inflammatory properties.
  • These activities underpin their use in treating acne, psoriasis, photoaging, precancerous lesions, and cancers.
  • Side effects of all trans-retinoic acid (RA) limit chronic dermatologic use.

Purpose of the Study:

  • To review the therapeutic applications of retinoids in dermatology and oncology.
  • To discuss the development and potential of receptor-selective retinoids.
  • To explore novel retinoid targets and therapeutic opportunities.

Main Methods:

  • Review of existing literature on retinoid synthesis and receptor interactions.
  • Analysis of structure-activity relationships for retinoic acid receptor (RAR) and retinoid X receptor (RXR) ligands.

Related Experiment Videos

  • Examination of pre-clinical data for novel retinoids in various disease models.

    • Main Results:

    • Two topical drugs, tazarotene (Tazorac) and adapalene (Differin), target RARs and are approved for acne and psoriasis.
    • Subtype-specific RAR retinoids are in pre-clinical development for cancers, psoriasis, and mitigating Accutane toxicity.
    • RXR-specific retinoids demonstrated efficacy in treating hyperglycemia in type II diabetes models.

    Conclusions:

    • Advancements in retinoid synthesis and understanding of retinoid receptor (RAR/RXR) mechanisms are expanding therapeutic potential.
    • Novel retinoids offer improved treatments for existing conditions and identify new therapeutic targets.
    • Receptor-selective retinoids hold promise for diverse indications beyond dermatology, including metabolic disorders.